WHO Bioequivalence Guideline Update 2026: The Future Of Global Generic Drug Compliance

WHO 2026 Draft Bioequivalence Guideline: What Pharmaceutical Companies Must Know

The global regulatory landscape for generic medicines and multisource pharmaceutical products is rapidly evolving.

The World Health Organization (WHO) released a draft update to its Bioequivalence (BE) guidance for Immediate Release (IR) oral dosage forms in April 2026. The revised guidance aligns more closely with ICH M13A, ICH M10, and ICH M9 principles while introducing updated expectations for bioequivalence studies, data integrity, pH-dependent drug products, endogenous compounds, BCS biowaivers, and multisource generic medicines.

On 24 April 2026, the World Health Organization (WHO) released a draft working document titled:

“Bioequivalence for Immediate Release Oral Dosage Forms” (QAS/25.990)

The guidance was published for public consultation and aims to modernize WHO recommendations for demonstrating bioequivalence (BE) for orally administered immediate-release pharmaceutical products.

This includes:

• Tablets 
• Capsules 
• Oral suspensions 
• Oral solutions 
• Chewable tablets 
• Orally disintegrating tablets (ODTs) 
• Fixed-dose combination products 

This update represents far more than a routine revision.

It signals WHO’s broader strategy to:

• Align with evolving ICH guidance 
• Improve global regulatory harmonization 
• Strengthen data integrity expectations 
• Support consistent generic drug approvals worldwide 

For pharmaceutical manufacturers, CROs, and regulatory affairs teams, the draft guidance creates important strategic implications for 2026 and beyond.

Why the WHO Bioequivalence Update Matters

Bioequivalence studies remain one of the most critical components of generic drug development and regulatory approval.

Demonstrating BE ensures a generic medicine performs similarly to a reference product in terms of:

• Safety 
• Efficacy 
• Pharmacokinetics (PK) 
• Therapeutic performance 

The updated WHO draft guidance aims to provide:

• Greater scientific consistency
• Improved regulatory clarity
• Alignment with international expectations
• Better support for WHO Member States and emerging markets

Key Objectives of the WHO 2026 BE Update

What Triggered the WHO Revision?

According to WHO, the revision was recommended by the:

58th Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP)

The update followed discussions from the:

2024 Joint Meeting on Regulatory Guidance for Multisource Products

WHO noted that although many scientific principles align with existing guidance, several technical areas required further clarification and modernization.

Key Areas Receiving Updated Regulatory Attention

The draft guidance highlights several important focus areas, including:

• Dose proportionality 
• Endogenous compounds 
• pH-dependent drug products 
• Bioequivalence study design modernization 
• Fixed-dose combinations 
• Data integrity expectations 
• Statistical evaluation approaches 

Stronger Alignment with ICH Guidance

One of the most significant developments is WHO’s increasing alignment with:

• ICH M9
• ICH M10
• ICH M13A

This reflects continued global convergence in pharmaceutical regulatory science.

ICH Guidelines Referenced in the WHO Draft

Scope of the WHO Draft Guidance

The draft guidance applies to:

• Immediate Release (IR) oral dosage forms
• Tablets and capsules
• Oral suspensions and solutions
• Chewable formulations
• Orally disintegrating tablets (ODTs)
• Fixed-dose combinations

The guideline primarily focuses on:

Pharmacokinetic (PK)-based bioequivalence studies

However, WHO also confirms that:

• Comparative dissolution testing
• BCS-based biowaivers

may still be appropriate in certain situations.

Data Integrity Receives Greater Attention

One of the most notable aspects of the draft guidance is the stronger emphasis on:

Data integrity and GCP compliance

WHO clearly states that sponsors remain fully responsible for the integrity, traceability, and reliability of submitted study data.

The guidance reinforces alignment with:

WHO Good Clinical Practice (GCP) principles

WHO Data Integrity Expectations

Impact on Generic Drug Manufacturers

For companies developing multi-source generic medicines, the updated guidance may directly affect:

• BE study protocols 
• Statistical analysis methods 
• Dissolution testing strategies 
• CRO oversight programs 
• BCS biowaiver evaluations 
• Regulatory submission planning 
• Global market access strategies 

Companies operating across emerging markets should pay close attention, as WHO guidance heavily influences many national regulatory authorities worldwide.

Global Regulatory Impact Beyond WHO

WHO bioequivalence guidance is widely referenced by:

• Emerging market regulators 
• Public health procurement agencies 
• International pharmaceutical programs 
• Generic medicine approval authorities 

As a result, updates to WHO guidance can significantly impact:

• Global generic drug development
• Multi-country dossier preparation
• International registration planning
• Regulatory harmonization efforts

Key Compliance Trends Emerging in 2026

Regulatory Trends to Watch

• Increased harmonization with ICH
• Stronger data governance expectations
• Greater scrutiny of complex generics
• Expanded focus on pH-dependent products
• Risk-based regulatory evaluation models

Strategic Priorities for Pharmaceutical Companies

Public Consultation Timeline

WHO opened the draft guidance for public consultation through the:

Please Review™ platform

Comment Deadline:
23 June 2026

WHO also indicated the draft may be reviewed during the:

59th ECSPP Meeting
12–16 October 2026

Formal adoption could follow committee review and stakeholder consultation.

How Maven Regulatory Solutions Supports Bioequivalence Compliance

At Maven Regulatory Solutions, we support pharmaceutical organizations with science-driven regulatory strategies for evolving global bioequivalence requirements.

Our Expertise Includes:

• Bioequivalence regulatory consulting
• Generic drug dossier support
• WHO & ICH compliance alignment
• Dissolution testing strategy
• BCS biowaiver evaluation
• Bioanalytical documentation review
• Data integrity & GCP readiness

Conclusion

The WHO’s 2026 draft guidance on bioequivalence for immediate-release oral dosage forms represents a major step toward global pharmaceutical regulatory harmonization.

By aligning more closely with ICH principles while strengthening expectations around:

• Scientific rigor
• Data integrity
• Risk-based evaluation
• Harmonized BE standards

The guidance signals the future direction of generic drug regulation worldwide.

Pharmaceutical companies that proactively adapt their bioequivalence strategies now will be better positioned to:

• Accelerate approvals
• Reduce regulatory risk
• Strengthening global market access
• Maintain long-term compliance confidence

The future of pharmaceutical regulation is becoming increasingly:

Global, harmonized, science-driven, and data-focused.

FAQs

1. What is the WHO 2026 bioequivalence guideline update?

It is a draft WHO guidance updating bioequivalence expectations for immediate-release oral dosage forms.

2. What products are covered under the guidance?

Tablets, capsules, oral suspensions, oral solutions, chewable, ODTs, and fixed-dose combinations.

3. Which ICH guidelines are referenced?

The draft references ICH M9, ICH M10, and ICH M13A.

4. Why is data integrity emphasized?

WHO increasingly expects traceable, validated, and reliable study data aligned with GCP principles.

5. What is the consultation deadline?

23 June 2026.

6. When could the guidance be adopted?

Potentially following review during the 59th ECSPP meeting in October 2026.

7. Why does WHO bioequivalence guidance matter globally?

Many emerging market regulators and procurement agencies rely on WHO guidance for generic medicine approvals.